scholarly journals Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment

Epigenomics ◽  
2020 ◽  
Vol 12 (15) ◽  
pp. 1317-1332
Author(s):  
Madonna R Peter ◽  
Misha Bilenky ◽  
Ruth Isserlin ◽  
Gary D Bader ◽  
Shu Yi Shen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Castration Resistant Prostate Cancer ◽  
Clinical Progression ◽  
Cell Free Dna ◽  
Targeting Therapy ◽  
Castration Resistant ◽  
Free Dna ◽  
Aggressive Form ◽  
Genome Wide

Aim: We examined methylation changes in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC) during treatment. Patients & methods: Genome-wide methylation analysis of sequentially collected cfDNA samples derived from mCRPC patients undergoing androgen-targeting therapy was performed. Results: Alterations in methylation states of genes previously implicated in prostate cancer progression were observed and patients that maintained methylation changes throughout therapy tended to have a longer time to clinical progression. Importantly, we also report that markers associated with a highly aggressive form of the disease, neuroendocrine-CRPC, were associated with a faster time to clinical progression. Conclusion: Our findings highlight the potential of monitoring the cfDNA methylome during therapy in mCRPC, which may serve as predictive markers of response to androgen-targeting agents.

scholarly journals Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment

2020 ◽  
Author(s):  
Madonna R. Peter ◽  
Misha Bilenky ◽  
Ruth Isserlin ◽  
Gary D. Bader ◽  
Shu Yi Shen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Castration Resistant Prostate Cancer ◽  
Clinical Progression ◽  
Cell Free Dna ◽  
Targeting Therapy ◽  
Castration Resistant ◽  
Free Dna ◽  
Aggressive Form ◽  
Genome Wide

AbstractAimWe examined methylation changes in cell-free DNA (cfDNA) in metastatic castration resistant prostate cancer (mCRPC) during treatment.Materials and MethodsGenome-wide methylation analysis of sequentially collected cfDNA samples derived from mCRPC patients undergoing androgen-targeting therapy was performed.ResultsAlterations in methylation states previously implicated in prostate cancer progression were observed and patients that maintained methylation changes throughout therapy tended to have a longer time to clinical progression (TTP). Importantly, we also report that markers associated with a highly aggressive form of the disease, Neuroendocrine-CRPC, were associated with a faster TTP.ConclusionOur findings highlight the potential of monitoring cfDNA methylome during therapy in mCRPC, which may serve as predictive markers of response to androgen-targeting agents.

Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer

2021 ◽  
pp. clincanres.2328.2021
Author(s):  
Kei Mizuno ◽  
Takayuki Sumiyoshi ◽  
Takatsugu Okegawa ◽  
Naoki Terada ◽  
Satoshi Ishitoya ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Low Frequency ◽  
Clinical Impact ◽  
Castration Resistant Prostate Cancer ◽  
Cell Free Dna ◽  
Castration Resistant ◽  
Free Dna

Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 5014-5014 ◽  
Author(s):  
Niven Mehra ◽  
Rossitza Christova ◽  
Lorna Pope ◽  
Suzanne Carreira ◽  
Jane Goodall ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Plasma Cell ◽  
Castration Resistant Prostate Cancer ◽  
Cell Free Dna ◽  
Dna Concentration ◽  
Castration Resistant ◽  
Free Dna
Sign in / Sign up

Export Citation Format

Share Document